NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Completes QM CoRE(TM) Integration
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine (CoRE(TM)). According to the update, CoRE was integrated with Helomics’ proprietary TumorSpace(TM) knowledgebase of 150,000 tumor drug response profiles and the TruTumor(TM) patient primary tumor cell line assay. The move allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic. “With the completion of the CoRE integration, we are now able to offer our new PeDAL(TM) (Patient-cEntric Discovery by Active Learning) service to pharmaceutical companies to allow patient-centric de-risking of compounds early in discovery, resulting in better prioritization of compounds and better coverage of patient diversity. This will dramatically improve the chances of successfully translating discoveries into the clinic, resulting in lowered costs, shortened timelines, and most importantly enhanced ‘speed-to-patient’ for new therapies,” explained Dr. Carl Schwartz, CEO of Predictive Oncology. “We expect to see revenue generating projects that use PeDAL and CoRE in the first half of 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine (CoRE(TM)). According to the update, CoRE was integrated with Helomics’ proprietary TumorSpace(TM) knowledgebase of 150,000 tumor drug response profiles and the TruTumor(TM) patient primary tumor cell line assay. The move allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic. “With the completion of the CoRE integration, we are now able to offer our new PeDAL(TM) (Patient-cEntric Discovery by Active Learning) service to pharmaceutical companies to allow patient-centric de-risking of compounds early in discovery, resulting in better prioritization of compounds and better coverage of patient diversity. This will dramatically improve the chances of successfully translating discoveries into the clinic, resulting in lowered costs, shortened timelines, and most importantly enhanced ‘speed-to-patient’ for new therapies,” explained Dr. Carl Schwartz, CEO of Predictive Oncology. “We expect to see revenue generating projects that use PeDAL and CoRE in the first half of 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
